MA52771A - Anticorps anti-cd33, anticorps bispécifiques anti-cd33/anti-cd3 et leurs utilisations - Google Patents
Anticorps anti-cd33, anticorps bispécifiques anti-cd33/anti-cd3 et leurs utilisationsInfo
- Publication number
- MA52771A MA52771A MA052771A MA52771A MA52771A MA 52771 A MA52771 A MA 52771A MA 052771 A MA052771 A MA 052771A MA 52771 A MA52771 A MA 52771A MA 52771 A MA52771 A MA 52771A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- bispecific antibodies
- bispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862676123P | 2018-05-24 | 2018-05-24 | |
| US201962825846P | 2019-03-29 | 2019-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52771A true MA52771A (fr) | 2021-04-14 |
Family
ID=67211770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052771A MA52771A (fr) | 2018-05-24 | 2019-05-21 | Anticorps anti-cd33, anticorps bispécifiques anti-cd33/anti-cd3 et leurs utilisations |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11466082B2 (fr) |
| EP (1) | EP3802606B1 (fr) |
| JP (1) | JP7530298B2 (fr) |
| KR (1) | KR102890653B1 (fr) |
| CN (1) | CN112189022B (fr) |
| AU (1) | AU2019274229B2 (fr) |
| BR (1) | BR112020023357A2 (fr) |
| CL (1) | CL2020003028A1 (fr) |
| CO (1) | CO2020014575A2 (fr) |
| CR (1) | CR20200567A (fr) |
| EC (1) | ECSP20075198A (fr) |
| ES (1) | ES2998890T3 (fr) |
| IL (1) | IL278844A (fr) |
| JO (1) | JOP20190116A1 (fr) |
| MA (1) | MA52771A (fr) |
| MX (1) | MX2020012588A (fr) |
| NI (1) | NI202000088A (fr) |
| PE (1) | PE20210180A1 (fr) |
| PH (1) | PH12020552010A1 (fr) |
| SG (1) | SG11202011210TA (fr) |
| TW (1) | TW202033551A (fr) |
| UY (1) | UY38242A (fr) |
| WO (1) | WO2019224711A2 (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201792581A1 (ru) | 2015-05-29 | 2018-07-31 | Амфивена Терапьютикс, Инк. | Способы применения биспецифических cd33- и cd3- связывающих белков |
| EP3824906A1 (fr) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Formulations d'anticorps anti-tnf alpha |
| MX420253B (es) | 2018-05-24 | 2025-02-10 | Janssen Biotech Inc | Anticuerpos anti-cd3 y usos de estos. |
| SG11202101552SA (en) | 2018-08-31 | 2021-03-30 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| DE102018127845A1 (de) | 2018-11-07 | 2020-05-07 | Grimme Landmaschinenfabrik Gmbh & Co. Kg | Verfahren zur Regelung des Betriebs einer Maschine zum Ernten von Hackfrüchten |
| CN114502584B (zh) * | 2019-02-22 | 2025-01-10 | 纪念斯隆凯特琳癌症中心 | Cd33抗体和使用所述抗体治疗癌症的方法 |
| JP2022521551A (ja) | 2019-02-26 | 2022-04-08 | ツイスト バイオサイエンス コーポレーション | Ｇｌｐ１受容体の変異体核酸ライブラリ |
| BR112022011235A2 (pt) | 2019-12-09 | 2022-12-13 | Twist Bioscience Corp | Bibliotecas de variantes de ácido nucleico para receptores de adenosina |
| CA3173268A1 (fr) * | 2020-02-27 | 2021-09-02 | Janssen Biotech, Inc. | Materiels et methodes de modulation d'une reponse immunitaire |
| US20210284731A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
| US20240293453A1 (en) * | 2020-03-13 | 2024-09-05 | Janssen Biotech, Inc. | Materials and methods for binding siglec-3/cd33 |
| CN115605512A (zh) * | 2020-03-13 | 2023-01-13 | 詹森生物科技公司（Us） | 用于调节δ链介导的免疫的材料和方法 |
| CA3172691A1 (fr) | 2020-03-31 | 2021-10-07 | Cameron J. Turtle | Recepteurs antigeniques chimeriques ciblant cd33 |
| EP4126925A4 (fr) * | 2020-03-31 | 2024-07-24 | Fred Hutchinson Cancer Center | Récepteurs antigéniques chimériques ciblant cd33 |
| WO2021202726A2 (fr) * | 2020-03-31 | 2021-10-07 | Fred Hutchinson Cancer Research Center | Anticorps anti-cd33 et leurs utilisations |
| WO2021231237A2 (fr) * | 2020-05-11 | 2021-11-18 | Augmenta Bioworks, Inc. | Anticorps anti sras-cov-2 et leurs utilisations |
| IL298444A (en) | 2020-05-27 | 2023-01-01 | Janssen Biotech Inc | Proteins containing cd3 antigen binding sites and uses thereof |
| EP4214233A1 (fr) | 2020-09-16 | 2023-07-26 | Amgen Inc. | Méthodes d'administration de doses thérapeutiques de molécules bispécifiques activant les lymphocytes t pour le traitement du cancer |
| KR20230147617A (ko) * | 2021-01-21 | 2023-10-23 | 트위스트 바이오사이언스 코포레이션 | 아데노신 수용체에 관한 방법 및 조성물 |
| PE20241170A1 (es) | 2021-02-16 | 2024-05-28 | Janssen Pharmaceutica Nv | Anticuerpo triespecifico dirigido a bcma, gprc5d, y cd3 |
| BR112023019484A2 (pt) | 2021-03-24 | 2023-12-05 | Janssen Biotech Inc | Anticorpo triespecífico que tem como alvo cd79b, cd20 e cd3 |
| WO2022228471A1 (fr) * | 2021-04-27 | 2022-11-03 | 上海驯鹿生物技术有限公司 | Cellule souche hématopoïétique génétiquement modifiée et son utilisation en combinaison avec lymphocyte car-t |
| EP4377354A4 (fr) * | 2021-07-30 | 2026-01-21 | Nanjing Legend Biotech Co Ltd | Anticorps anti-cd33 et leurs utilisations |
| CN118234750A (zh) * | 2021-09-02 | 2024-06-21 | 纪念斯隆-凯特琳癌症中心 | 抗cd33抗体和其用途 |
| US20240409634A1 (en) * | 2021-09-13 | 2024-12-12 | Janssen Biotech, Inc. | CD33 x Vd2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER |
| WO2023081898A1 (fr) * | 2021-11-08 | 2023-05-11 | Alector Llc | Cd33 soluble en tant que biomarqueur pour une efficacité anti-cd33 |
| JP2026502768A (ja) * | 2022-10-25 | 2026-01-27 | アブレクシス， エルエルシー | 抗ｃｄ３抗体 |
| WO2025120583A2 (fr) * | 2023-12-08 | 2025-06-12 | Janssen Biotech, Inc. | ANTICORPS CD33, ANTICORPS MULTISPÉCIFIQUES CD33/Vδ2 ET LEURS UTILISATIONS |
| WO2025149667A1 (fr) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Conjugués anticorps-médicament et leurs utilisations |
| WO2025174974A1 (fr) * | 2024-02-14 | 2025-08-21 | Bristol-Myers Squibb Company | Anticorps anti-cd33 et leurs utilisations |
| CN118221826B (zh) * | 2024-04-25 | 2024-11-15 | 北京绿竹生物技术股份有限公司 | 一种结合人cd33和cd3的双特异性抗体 |
| WO2026006495A1 (fr) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anticorps anti-wt1/hla-a2 et ses utilisations |
| WO2026006492A2 (fr) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anticorps anti-prame/hla-a2 et leurs utilisations |
| CN119804863B (zh) * | 2025-03-13 | 2025-06-17 | 北京华诺泰生物医药科技有限公司 | 检测人偏肺病毒抗原的酶联免疫试剂盒及定量检测方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| DK1578446T3 (en) | 2002-11-07 | 2015-06-29 | Immunogen Inc | ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT |
| AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| EP1940881B1 (fr) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations |
| EP2035456A1 (fr) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production d'anticorps bispécifiques |
| AU2008234019B2 (en) | 2007-04-03 | 2014-05-29 | Amgen Research (Munich) Gmbh | Cross-species-specific bispecific binders |
| WO2008119567A2 (fr) | 2007-04-03 | 2008-10-09 | Micromet Ag | Domaine de liaison spécifique d'espèces croisées |
| RU2769948C2 (ru) | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
| EP3106468A1 (fr) | 2008-10-01 | 2016-12-21 | Amgen Research (Munich) GmbH | Anticorps bispécifique à chaîne unique psmaxcd3 particulière d'une espèce à l'autre |
| AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| AU2009299793B2 (en) | 2008-10-01 | 2016-03-10 | Amgen Research (Munich) Gmbh | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| PL2560993T3 (pl) | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| AU2012332021B8 (en) | 2011-11-04 | 2017-10-12 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| EP4269602A3 (fr) | 2012-12-14 | 2023-12-27 | OmniAB, Inc. | Polynucléotides codant pour des anticorps de rongeur ayant des idiotypes humains, et animaux les comprenant |
| AR097648A1 (es) * | 2013-09-13 | 2016-04-06 | Amgen Inc | Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide |
| MX2016007576A (es) | 2013-12-13 | 2016-10-03 | Genentech Inc | Anticuerpos e inmunoconjugados anti-cd33. |
| US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| JO3568B1 (ar) * | 2014-09-05 | 2020-07-05 | Janssen Pharmaceutica Nv | عوامل ربط cd123 واستخداماتها |
| EP3307779A2 (fr) * | 2015-06-12 | 2018-04-18 | Alector LLC | Anticorps anti-cd33 et leurs procédés d'utilisation |
| CA2988982A1 (fr) * | 2015-06-12 | 2016-12-15 | Alector Llc | Anticorps anti-cd33 et leurs procedes d'utilisation |
| AU2018310985A1 (en) | 2017-08-03 | 2019-11-07 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| CA3091764A1 (fr) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Domaines variables d'anticorps ciblant cd33, et leur utilisation |
| MX420253B (es) * | 2018-05-24 | 2025-02-10 | Janssen Biotech Inc | Anticuerpos anti-cd3 y usos de estos. |
-
2018
- 2018-05-24 JO JOP/2019/0116A patent/JOP20190116A1/ar unknown
-
2019
- 2019-05-21 KR KR1020207036865A patent/KR102890653B1/ko active Active
- 2019-05-21 PE PE2020001885A patent/PE20210180A1/es unknown
- 2019-05-21 MX MX2020012588A patent/MX2020012588A/es unknown
- 2019-05-21 US US16/418,420 patent/US11466082B2/en active Active
- 2019-05-21 ES ES19737216T patent/ES2998890T3/es active Active
- 2019-05-21 MA MA052771A patent/MA52771A/fr unknown
- 2019-05-21 CN CN201980034952.6A patent/CN112189022B/zh active Active
- 2019-05-21 BR BR112020023357-9A patent/BR112020023357A2/pt unknown
- 2019-05-21 SG SG11202011210TA patent/SG11202011210TA/en unknown
- 2019-05-21 JP JP2020564908A patent/JP7530298B2/ja active Active
- 2019-05-21 CR CR20200567A patent/CR20200567A/es unknown
- 2019-05-21 AU AU2019274229A patent/AU2019274229B2/en active Active
- 2019-05-21 WO PCT/IB2019/054182 patent/WO2019224711A2/fr not_active Ceased
- 2019-05-21 EP EP19737216.2A patent/EP3802606B1/fr active Active
- 2019-05-23 TW TW108117806A patent/TW202033551A/zh unknown
- 2019-05-24 UY UY0001038242A patent/UY38242A/es unknown
-
2020
- 2020-11-19 IL IL278844A patent/IL278844A/en unknown
- 2020-11-20 CL CL2020003028A patent/CL2020003028A1/es unknown
- 2020-11-23 PH PH12020552010A patent/PH12020552010A1/en unknown
- 2020-11-23 EC ECSENADI202075198A patent/ECSP20075198A/es unknown
- 2020-11-23 NI NI202000088A patent/NI202000088A/es unknown
- 2020-11-24 CO CONC2020/0014575A patent/CO2020014575A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NI202000088A (es) | 2021-03-23 |
| JP2021524244A (ja) | 2021-09-13 |
| EP3802606A2 (fr) | 2021-04-14 |
| CR20200567A (es) | 2021-01-20 |
| UY38242A (es) | 2019-11-29 |
| WO2019224711A3 (fr) | 2020-01-02 |
| BR112020023357A2 (pt) | 2021-04-27 |
| SG11202011210TA (en) | 2020-12-30 |
| US20190382481A1 (en) | 2019-12-19 |
| AU2019274229B2 (en) | 2026-03-19 |
| AU2019274229A1 (en) | 2020-11-26 |
| CN112189022B (zh) | 2025-04-15 |
| ES2998890T3 (en) | 2025-02-24 |
| KR102890653B1 (ko) | 2025-11-24 |
| WO2019224711A2 (fr) | 2019-11-28 |
| CL2020003028A1 (es) | 2021-04-16 |
| PE20210180A1 (es) | 2021-01-29 |
| US11466082B2 (en) | 2022-10-11 |
| EP3802606B1 (fr) | 2024-10-09 |
| CN112189022A (zh) | 2021-01-05 |
| ECSP20075198A (es) | 2020-12-31 |
| JOP20190116A1 (ar) | 2019-11-24 |
| MX2020012588A (es) | 2021-04-28 |
| KR20210013156A (ko) | 2021-02-03 |
| IL278844A (en) | 2021-01-31 |
| PH12020552010A1 (en) | 2021-06-14 |
| CA3101270A1 (fr) | 2019-11-28 |
| CO2020014575A2 (es) | 2020-12-10 |
| TW202033551A (zh) | 2020-09-16 |
| JP7530298B2 (ja) | 2024-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52771A (fr) | Anticorps anti-cd33, anticorps bispécifiques anti-cd33/anti-cd3 et leurs utilisations | |
| FR25C1029I1 (fr) | Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations | |
| MA54539A (fr) | Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations | |
| MA52773A (fr) | Anticorps anti-cd3 et leurs utilisations | |
| MA54540A (fr) | Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations | |
| MA52970A (fr) | Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations | |
| EP3891187A4 (fr) | Anticorps bispécifiques anti-pd-l1/anti-4-1bb et leurs utilisations | |
| EP3891183A4 (fr) | Anticorps anti-claudine et leurs utilisations | |
| EP3759143A4 (fr) | Anticorps anti-tigit et leurs utilisations | |
| MA42935A (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
| EP3898691A4 (fr) | Anticorps trem2 et leurs utilisations | |
| EP3625263A4 (fr) | Anticorps anti-galectine-9 et leurs utilisations | |
| MA52949A (fr) | Anticorps anti-pd-1 et leurs utilisations | |
| MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
| EP3873512A4 (fr) | Anticorps epcam, anticorps activables, et immunoconjugués, et leurs utilisations | |
| EP3411069A4 (fr) | Anticorps humanisés anti-cd3, conjugués et leurs utilisations | |
| EP3897719A4 (fr) | Anticorps bispécifiques clivables par la protéase et utilisations associées | |
| EP3426686A4 (fr) | Anticorps anti-pacap humanisés et leurs utilisations | |
| MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
| EP3661555A4 (fr) | Anticorps bispécifiques et leurs utilisations | |
| EP3833693A4 (fr) | Anticorps bispécifiques anti-pd-l1/anti-lag3 et leurs utilisations | |
| EP3645563A4 (fr) | Anticorps anti-fam19a5 et leurs utilisations | |
| EP3966252A4 (fr) | Anticorps anti-cd137 humanisés et leurs utilisations | |
| EP3790586A4 (fr) | Anticorps anti-dll3 et leurs utilisations | |
| EP3850012A4 (fr) | Anticorps anti-tnfrsf9 et leurs utilisations |